Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885400 | 1.00 | FFAR1 (0.59) | FFAR1POLBACHEALDH1A1KDM4E | |
| SCHEMBL16232153 | 1.00 | FFAR1 (0.59) | FFAR1POLBACHEALDH1A1KDM4E | |
| SCHEMBL11488269 | 0.94 | FFAR1 (0.60) | FFAR1POLBACHEMME | |
| Azetidine SCHEMBL28221759 | 0.90 | FFAR1 (0.50) | FFAR1POLBACHEALDH1A1KDM4E | |
| SCHEMBL11332403 | 0.83 | FFAR1 (0.62) | FFAR1POLBACHEALDH1A1KDM4E | |
| SCHEMBL7565865 | 0.82 | POLB (0.47) | FFAR1POLBACHEALDH1A1KDM4E | |
| SCHEMBL16232164 | 0.82 | POLB (0.47) | FFAR1POLBACHEALDH1A1KDM4E | |
| SCHEMBL16232165 | 0.82 | POLB (0.47) | FFAR1POLBACHEALDH1A1KDM4E | |
| SCHEMBL12883179 | 0.82 | POLB (0.47) | FFAR1POLBACHEALDH1A1KDM4E | |
| SCHEMBL28770128 | 0.82 | POLB (0.47) | FFAR1POLBACHEALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
| US-9493451-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2016-11-15 | — | — | US | disclosed |
| US-9493451-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2016-11-15 | — | — | US | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-6858611-B2 | Potassium channel inhibitors | ICAGEN, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030236261-A1 | Potassium channel inhibitors | ICAGEN, INC. (US) | 2003-12-25 | — | — | US | disclosed |
| US-6566380-B2 | For therapy of cardiac arrhythmias | ICAGEN, INC. | 2003-05-20 | — | — | US | disclosed |
| EP-1305288-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030027829-A1 | Amide substituted heteroaromatic bicylcyclic or tetrahydronaphthalene sulfonamide compounds are useful for treating arrhythmia | ICAGEN, INC. | 2003-02-06 | — | — | US | disclosed |
| WO-2002008191-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| CN-1314906-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | FFAR1 2942/4885POLB 3795/4885ACHE 712/4885 |
| US-20030236261-A1 | Potassium channel inhibitors | KCNN2, KCNH2, KCNJ2 | FFAR1 3392/4885POLB 3642/4885ACHE 2642/4885 |
| US-20030027829-A1 | Amide substituted heteroaromatic bicylcyclic or tetrahydronaphthalene sulfonamide compounds are useful for treating arrhythmia | KCNH1, KCNH2, KCNN2 | FFAR1 1789/4885POLB 3758/4885ACHE 4104/4885 |
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | FFAR1 235/4885POLB 4515/4885ACHE 418/4885 |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | FFAR1 2942/4885POLB 3795/4885ACHE 712/4885 |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | FFAR1 2942/4885POLB 3795/4885ACHE 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.